Drugs / HSV 2 Formulation 4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04222985 | Feb 2020 → May 2021 | genital herpes | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSV 2 Formulation 4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04222985 ↗ |
| Modality | Vaccine | “4 Investigational HSV 2 Vaccines” NCT04222985 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04222985 ↗ |